Clinical trials: Macular Neovascularisation
Neovascular Age-related Macular Degeneration
An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD
This study was designed to evaluate a variable dosing regimen with intravitreal ranibizumab for the treatment of patients with neovascular age-related macular degeneration (AMD) in the Prospective OCT Imaging of Patients with…
- Trial name
- NCT00373659
- Testing
- Ranibizumab (Lucentis)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Miami
Age Related Macular Degeneration (AMD), Macular Degeneration
An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD
The purpose of this study is to determine the benefits of treating subjects with neovascular age-related macular degeneration (AMD) at an earlier stage of choroidal neovascularization (CNV) as compared to those with established…
- Conditions
- Age Related Macular Degeneration (AMD), Macular Degeneration, Choroidal Neovascularization (CNV)
- Trial name
- PERSPECTIVES (NCT00327470)
- Testing
- Pegaptanib Sodium 0.3 mg
- Where
- 58 sites in Austria, Belgium and 13 more
- Volunteers
- 288 people
- Sponsor
- Pfizer
Diabetic Retinopathy, Diabetic Macular Edema
Bevacizumab Versus Ranibizumab for Diabetic Retinopathy
Treatment of diabetic macular edema with perifoveal focal/grid laser coagulation was found to be effective saving the visual acuity only in 50% of patients and only 3-14% of treated patients had an improved visual acuity…
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, Proliferative Diabetic Retinopathy
- Trial name
- NCT00545870
- Testing
- bevacizumab, Ranibizumab
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Ursula Schmidt-Erfurth, M.D.
Macular Edema, Retinal Vein Occlusion
An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
This is an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported separately under FVF3426g, NCT00379795) enrolled subjects with primary or recurrent…
- Trial name
- NCT01442064
- Testing
- Ranibizumab 0.5 mg
- Volunteers
- 608 people
- Sponsor
- Genentech, Inc.